Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development

Journal of Virology

Volumn 71, Issue 11, 1997, Pages 8615-8623

  Cao, Huyen ^a,f   Kanki, Phyllis ^b   Sankalé, Jean Louis ^b   Dieng Sarr, Abdoulaye ^b   Mazzara, Gail P ^c   Kalams, Spyros A ^a   Korber, Bette ^d   Mboup, Souleymane ^e   Walker, Bruce D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Therion Biologics Corporation   (United States)

^d LOS ALAMOS NATIONAL LABORATORY   (United States)

^e UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; RNA DIRECTED DNA POLYMERASE;

AMINO ACID SUBSTITUTION; ARTICLE; CONSENSUS SEQUENCE; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLOTTING; IMMUNOGENICITY; PRIORITY JOURNAL; VIRUS RECOMBINANT;

EID: 0030846020     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.11.8615-8623.1997     Document Type: Article

References (65)

1. Allsopp, C., R. Harding, C. Taylor, M. Bunce, D. Kwiatkowski, N. Anstey, D. Brewster, A. McMichael, B. Greenwood, and A. Hill. 1992. Interethnic genetic differentiation in Africa: HLA class I antigen in The Gambia. Am. J. Hum Genet. 50:411-421.
2. Bergmann, C. C., Q. Yao, C. Ho, and S. L. Bukwold. 1996. Flanking residues alter antigenicity and immunogeniciry of multi-unit CTL epitopes. J. Immunol. 157:3242-3249.
3. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
4. Borrow, P., H. Lewicki, X. Wei, M. S. Horwitz, N. Peffer, H. Meyers, J. A. Nelson, J. E. Gairin, B. Hahn, M. B. Oldstone, and G. M. Shaw. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3:205-211.
5. Brander, C., and B. Walker (ed.). 1995. The HLA-class I restricted CTL response in HIV-1 infection: identification of optimal epitopes, vol. 1. Theoretical Biology and Biophysics, Los Alamos, N. Mex.
6. Brander, C., and B. Walker (ed.). 1996. The HLA-class I restricted CTL response in HIV-1 infection: systematic identification of optimal epitopes, vol. 1. Theoretical Biology and Biophysics, Los Alamos, N. Mex.
7. Burke, D. S., and F. E. McCutchan. 1996. Global distribution of human immunodeficiency virus-1 clades, p. 119-126. In V. T. J. DeVita, S. Hellman, and S. A. Rosenberg (ed.), AIDS: etiology, diagnosis, treatment and prevention, 4 ed. Lippincott-Raven, Philadelphia, Pa.
8. Byrne, J. A., and M. B. Oldstone. 1984. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. J. Virol. 51:682-686.
9. Carr, J. K., M. O. Salminen, C. Koch, D. Gotte, A. W. Artenstein, P. A. Hegerich, D. St. Louis, D. S. Burke, and F. E. McCutchan. 1996. Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J. Virol. 70:5435-5943.
10. Cease, K. B.. and J. A. Berzofsky. 1994. Toward a vaccine for AIDS: the emergence of immunohiology-hased vaccine development. Annu. Rev Immunol. 12:423-489.
11. Collier, A. C., R. Coobs, D. A. Schoenfeld, R. L. Bassett, J. Timpone, A. Baruch, M. Jones, K. Facey, C. Whitacre, V. J. McAuliffe, H. M. Firedman. T. C. Merigan, R. C. Reichman, C. Hooper, L. Corey, and A. C. T. Group. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitahine. N. Engl. J. Med. 334:1011-1017.
12. Del Val, M., H.-J. Schlicht, T. Ruppert, M. J. Reddenase, and U. Koszinowski. 1991. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighbouring residues in the protein. Cell 66:1145-1153.
13. Dolin, R. 1995. Human studies in the development of human immunodeficiency virus vaccines. J. Infect. Dis. 172:1175-1183.
14. Earl, P. L., S. Koenig, and B. Moss. 1991. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J. Virol. 65:31-41.
15. Esparza, J., S. Osmanov, and W. Heyward. 1995. HIV preventive vaccines. Drugs 50:792-804.
16. Ferrari, G., W. Humphrey, M. J. McElrath, J. Excler, A. Duliege, M. L. Clements, L. C. Corey, D. P. Bolognesi, and K. J. Weinhold. 1997. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Natl. Acad. Sci. USA 94:1396-1401.
17. Gao, F., D. L. Robertson, S. G. Morrison, H. Hui, S. Craig, J. Decker, P. N. Fultz, M. Girard, G. M. Shaw, B. H. Hahn, and P. M. Sharp. 1996. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J. Virol 70:7013-7029.
18. Graham, B. S., and P. F. Wright. 1995. Candidate AIDS vaccines. N. Engl J. Med. 333:1331-1339.
19. Gritz, L., A. Destree, N. Cormier, E. Day, V. Stallard, T. Caiazzo, G. Mazzara, and D. Panicali. 1990. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J. Virol. 64:5948-5957.
20. Harrer, E., T. Harrer, S. Buchbinder, D. Mann, M. Feinberg, T. Yilma, R. Johnson, and B. Walker. 1994. HIV-1-specific cytotoxic T lymphocytes response in healthy, long-term nonprogressing seropositive persons. AIDS Res. Hum. Retroviruses 10:S77-S78.
21. Harrer, T., E. Harrer, T. Elbeik, S. Staprans, M. B. Feinberg, Y. Cao, D. D. Ho, T. Yilma, A. M. Caliendo, R. P. Johnson, S. P. Buchbinder, and B. D. Walker. 1996. Strong cytotoxic T cells and weak neutralizing antibodies in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res. Hum. Retroviruses 12:585-592.
22. Harrer, T., E. Harrer, S. A. Kalams, P. Barbosa, A. Trocha, R. P. Johnson, T. Elbeik, M. B. Feinberg, S. P. Buchbinder, and B. D. Walker. 1996. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J. Immunol. 156:2616-2623.
23. Haynes, B. F. 1996. HIV vaccines: where we are and where we arc going. Lancet. 348:933-937. (Review.)
24. Haynes, B. F., G. Pantaleo, and A. S. Fauci. 1996. Toward an understanding of the correlates of protective immunity to HIV infection. Science 271:324-328.
25. Heslop, H. E., C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney. 1996. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2:551-555.
26. Jassoy, C., R. P. Johnson, B. A. Navia, J. Worth, and B. D. Walker. 1992. Detection of a vigorous HIV-1-specific cytotoxic T lymphocyte response in cerebrospinal fluid from infected persons with AIDS dementia complex. J. Immunol. 149:3113-3119.
27. Johnson, R. P., A. Trocha, T. M. Buchanan, and B. D. Walker. 1992. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the HIV-1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation. J. Exp. Med. 175:961-971.
28. Johnson, R. P., A. Trocha, L. Yang, G. Mazzara, D. Panicali, T. Buchanan, and B. D. Walker. 1991. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes: fine specificity of the gag-specific response by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J. Immunol. 147:1512-1521.
29. Johnson, R. P., A. Trocha, L. Yang, G. P. Mazzara, D. L. Panicali, T. M. Buchanan, and B. D. Walker. 1991. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J. Immunol. 147:1512-1521.
30. Kalams, S., R. P. Johnson, M. J. Dynan, K. E. Hartman, T. Harrer, E. Harrer, A. K. Trocha, W. A. Blattner, S. P. Buchbinder, and B. D. Walker. 1996. T cell receptor usage and fine specificity of human immunodeficiency virus-1-specific cytotoxic T lymphocyte clones: analysis of quasispecies recognition reveals a dominant response directed against a minor in vivo variant. J. Exp. Med. 183:1669-1679.
31. Kanki, P. 1996. Epidemiology and natural history of HIV-2, p. 97-108. In V. DeVita, S. Hellman, and S. Rosenberg (ed.), AIDS: etiology, diagnosis, treatment and prevention, 4 ed. Eippincott-Raven Co., Philadelphia, Pa.
32. Kanki, P., S. Mboup, R. Marlink, K. Travers, C. Ksieh, A. Gueye, C. Boye, J. Sankale, C. Donnelly, W. Leisenring, T. Siby, I. Thior, M. Dia, E. Gueye, I. N'Doye, and M. Essex. 1992. Prevalence and risk determinants of human immunodeficiency virus type 2 (HIV-2) and human immunodeficiency virus type 1 (HIV-1) in West African female prostitutes. Am. J. Epidemiol. 136: 895-907.
33. Klein, M. R., C. A. van Baalen, A. M. Holwerda, S. R. Kerkhof Garde, R. J. Bende, I. P. Keet, J. K. Eeftinck-Schattenkerk, A. D. Osterhaus, H. Schuitemaker, and F. Miedema. 1995. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181:1356-1372.
34. Korber, B., C. Brander, J. Moore, P. D'Souza, B. Walker, R. Koup, J. Moore, B. Haynes, and G. Myers (ed.). 1996. HIV molecular immunology database 1996. Theoretical Biology and Biophysics, Los Alamos, N. Mex.
35. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
36. Koup, R. A., J. L. Sullivan, P. H. Levine, F. Brewster, A. Mahr, G. Mazzara, S. McKenzie, and D. Panicali. 1989. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J. Virol. 63:584-590.
37. Langlade-Demoyen, P., N. Ngo-Giang-Huong, and E. Oksendhendler. 1994. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contacts of HIV-infected patients. J. Clin. Invest. 93:1293-1297.
38. Lervin, N. L. 1993. Vaccines against human immunodeficiency virus-progress and prospects. N. Engl. J. Med. 329:1400-1405.
39. Louwagie, J., F. E. McCutchan, G. Eddy, M. Peeters, M. Fransen, G. Van Der Groen, H. Van Heuverswtn, and D. S. Burke. Utilization of genetic signature sequences distinguishing international HIV-1 isolates for typing by polymerase chain reaction. AIDS Res. Hum. Retroviruses 9:S147-S150.
40. Lubaki, M. N., M. A. Egan, R. F. Siliciano, K. J. Weinhold, and R. C. Bollinger. 1994. A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. AIDS Res. Hum. Retroviruses 10: 1427-1431.
41. Marlink, R., P. Kanki, I. Thior, K. Travers, G. Eisen, T. Siby, I. Traore, C. Hsieh, M. Dia, E. Gueye, J. Hellinger, A. Gueye-Ndiaye, J. Sankale, I. Ndoye, S. MBoup, and M. Essex. 1994. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265:1587-1590.
42. + cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J. Immunol. 148:1359-1366.
43. Myers, G., B. Korber, B. H. Hahn, K. T. Jeang, J. W. Mellors, F. E. McCutchan, L. E. Henderson, and G. N. Pavlakis. 1995. Human retroviruses and AIDS 1995: a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos National Laboratory, Los Alamos, N. Mex.
44. Neisig, A., J. Roelse, A. J. Sijts, F. Ossendorp, M. C. Keltkamp, W. M. Kast, C. J. Melief, and J. J. Neefjes. 1995. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J. Immunol. 154:1273-1279.
45. Nickolic-Zugic, J., and F. R. Carbone. 1991. Peptide presentation by class-I major histocomplex molecules. Immunol. Res. 10:54-65.
46. Over, M., and P. Piot. 1996. Human immunodeficiency virus infection and other sexually transmitted diseases in developing countries: public health importance and priorities for resource allocation. J. Infect. Dis. 174:S162-S175.
47. Pinto, L. A., J. Sullivan, J. A. Berzofsky, M. Clerici, H. A. Kessler, A. L. Landay, and G. M. Shearer. 1995. ENV-speciric cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J. Clin. Invest. 96:867-876.
48. Reddehase, M. J., F. Weiland, K. Muench, S. Jonjic, A. Lueske, and U. Koszinowski. 1985. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J. Virol. 55:264-273.
49. Reddehase, M. J., F. Weiland, K. Munch, S. Jonjie, A. Luske, and U. H. Koszinowski. 1987. CD8-positive lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J. Virol. 61:3102-3108.
50. Rinaldo, C., X.-L. Huang, Z. Fan, M. Ding, L. Beltz, A. Logar, D. Panicali, G. Mazzara, J. Liebmann, M. Cottrill, and P. Gupta. 1995. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:5838-5842.
51. Rowland-Jones, S., J. Sutton, K. Ariyoshi, T. Dong, F. Gotch, S. McAdam, D. Whitby, S. Sabally, A. Gallimore, T. Corrah, et al. 1995. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1:59-64. (Erratum, 1:598.)
52. Sethi, K. K., Y. Omata, and K. E. Schneweis. 1983. Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes. J. Gen. Virol. 64:443-447.
53. Smith, K., V. Stallard, J. Roos, C. Hart, N. Cormier, L. Cohen, B. Roberts, and L. Payne. 1993. Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences. Vaccine 11:43-53.
54. Tsomides, T. J., A. Aldovini, R. P. Johnson, B. D. Walker, R. A. Young, and H. N. Eisen. 1994. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1 (HIV-1). J. Exp. Med. 180:1283-1293.
55. Tsomides, T. J., B. D. Walker, and H. N. Eisen. 1991. An optimal viral peptide recognized by CDS+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc. Natl. Acad. Sci. USA 88:11276-11280.
56. Tsuji, K., M. Aizawa, and T. Sasasuki (ed.). 1991. HLA 1991. Proceedings of the Eleventh International Histocompatability Workshop and Conference. Oxford University Press, Yokohama, Japan.
57. Walker, B. D., S. Chakrabarti, B. Moss, T. J. Paradis, T. Flynn, A. G. Durno, R. S. Blumberg, J. C. Kaplan, M. S. Hirsch, and R. T. Schooley. 1987. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328:345-348.
58. Walker, B. D., C. Flexner, L. K. Birch, L. Fisher, T. J. Paradis, A. Aldovini, R. Young, B. Moss, and R. T. Schooley. 1989. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86:9514-9518.
59. Walker, B. D., C. Flexner, T. J. Paradis, T. C. Fuller, M. S. Hirsch, R. T. Schooley, and B. Moss. 1988. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 240:64-66.
60. Walter, E., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddel. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038-1044.
61. Wilson, C. C., J. T. Wong, D. Girard, D. P. Merril, M. Dynan, D. An, S. A. Kalams, R. P. Johnson, M. S. Hirsch, R. T. D'Aquila, and B. D. Walker. 1995. Ex vivo expansion of CD4+ lymphocytes from HIV-1 infected persons in the presence of combination antiretroviral therapy. J. Infect. Dis. 172:88-96.
62. Wolinsky, S. M., C. M. Wike, B. T. Korber, C. Hutto, W. P. Parks, L. L. Rosenblum, M. R. Furtado, and J. L. Munoz. 1992. Selective transmission of human immunodeficiency virus type 1 variants from mothers to infants. Science 255:1134-1137.
63. Wong, J. T., and R. B. Colvin. 1987. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J. Immunol. 139:1369-1374.
64. World Health Organization. 1996. Global situation of the HIV/AIDS pandemic. Weekly Epidemiol. Rec. 71:361-363.
65. Yap, K. L., G. L. Ada, and I. F. McKenzie. 1978. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 273: 238-239.